MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE

The invention discloses compounds of Formula (I):wherein A1, R1, R2, R3, R4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis and pharmaceutical compositions comprising the same. Also disclosed are methods for their production...

Full description

Saved in:
Bibliographic Details
Main Authors PIZZONERO, Mathieu Rafaël, COUTY, Sylvain, KYM, Philip R, PICOLET, Olivier Laurent, DESROY, Nicolas, LIU, Bo, SEARLE, Xenia B, VAN DER PLAS, Steven Emiel, MALAGU, Karine Fabienne, WANG, Xueqing, MAI, Thi Thu Trang, GFESSER, Gregory A, YEUNG, Ming C, BOGDAN, Andrew, MERAYO MERAYO, Nuria, ALTENBACH, Robert J, HOUSSEMAN, Christopher Gaëtan
Format Patent
LanguageEnglish
French
German
Published 18.08.2021
Subjects
ACYCLIC OR CARBOCYCLIC COMPOUNDS
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The invention discloses compounds of Formula (I):wherein A1, R1, R2, R3, R4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis and pharmaceutical compositions comprising the same. Also disclosed are methods for their production and methods of treating cystic fibrosis by administering the compounds.
Bibliography:Application Number: EP20210164249